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BACKGROUND: The aim of this study was to evaluate the effect of the benzoporphyrin derivative monoacid ring
A (vertepor®n)-mediated photodynamic therapy (PDT) on rat endometrium and to determine the optimal drug
concentration for endometrial ablation. METHODS: Five minutes after i.v. injection of different concentrations of
vertepor®n into 24 female Sprague±Dawley rats, 630 nm light treatment was delivered for 500 s (120 J/cm2) to the
left horn of the uterus. The 24 rats were divided into six groups according to the drug dose injected, four rats per
group: group I (2 mg/kg), group II (1 mg/kg), and groups III, IV, V and VI with 0.5, 0.25, 0.125 and 0.0625 mg/kg
respectively. Four days later, the rat uteri were analysed by light microscopy. RESULTS: Endometrial
destruction was seen in all six groups, with the most signi®cant result in group I (P < 0.008). Conservation of the
myometrium was most signi®cant in groups III, IV, V and VI. Acute in¯ammatory cells in the stromal
endometrium were recorded mainly in groups I and II. However, the drug dosage that was most signi®cant in
destroying the glands with conservation of the myometrium and not causing severe in¯ammation was between
0.5 and 0.125 mg/kg. CONCLUSIONS: Vertepor®n was effective in endometrial ablation in all our animal groups,
and the dose range of 0.5±0.125 mg/kg appeared to be adequate. This observation will have to be scaled for clinical
application.
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Introduction
Hysterectomy is one of the most frequently performed major
operations in the Western world. The indications for hyster-
ectomy are numerous and include malignant and benign
conditions, with dysfunctional uterine bleeding accounting for
~20% of hysterectomy cases (Lee et al., 1984). This procedure
may result in high annual hospitalization costs, morbidity rates
ranging from 20 to 40% and mortality from 0.06 to 0.38%,
depending on the procedure and the indication (Carlson et al.,
1993). In addition to the use of photodynamic therapy (PDT)
for macular degeneration as well as many oncological condi-
tions, numerous studies have proven PDT's role in endometrial
ablation (Wyss et al., 1994a;b; Gannon et al., 1995; Fehr et al.,
1996a;b, 2002; Steiner et al., 1996; Allison et al., 2001; Renno
and Miller, 2001; Major et al., 2002). As it can be performed in
an ambulatory setting with essentially no side effects, PDT
could be an ideal substitute for hysterectomy in treating
patients suffering from uterine bleeding dysfunction.
PDT uses the light activation of a photosensitizer to generate
highly reactive oxygen intermediates, leading to tissue destruc-
tion by apoptosis and/or necrosis (Sickenberg et al., 2000).
Various photosensitizers, such as 5-aminolevulinic acid (ALA)
and benzoporphyrin derivative (BPD), administered topically
or systemically, have been used for endometrial ablation in
animal models with good results (Wyss et al., 1994a; b; Gannon
et al., 1995; Fehr et al., 1996a;b; Steiner et al., 1996). However,
most of these studies targeted the endometrial glands directly
by either topical or systemic application of a photosensitizer. In
order to accumulate the photosensitizer in the endometrial
glands, long intervals between drug administration and light
application were needed.
BPD-monoacid ring A (BPD-MA), vertepor®n
(Visudyne)Ô, is a second-generation photosensitizer injected
in a liposomal formulation, which has been accepted by many
health authorities as a new and effective treatment for macular
degeneration. Despite the typical activation of the vertepor®n
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at a wavelength of 690 nm, it can also be activated at 630 nm
(Water®eld et al., 1994; Panjehpour et al., 2002). In the present
study, because of the thickness of the rat uterus, activation at a
wavelength of 630 nm is desirable, since deeper penetration at
690 nm is not necessary. The drug becomes effective within
minutes after injection and it is rapidly eliminated within 24 h
from the tissues, resulting in a skin photosensitivity that lasts
<2 days in general (Richter et al., 1993). In a previous study,
we showed that by using tin ethyl etiopurpurin as a
photosensitizer we could target the vasculature using a short
drug±light interval, resulting in effective photodynamic
therapy (Major et al., 1999a;b). In the present study, we
decided to evaluate the structural effect of PDT with a second-
generation dye BPD-MA (vertepor®n) on the rat uterus by
using it in an intravenous injection and with a short drug-light
interval of 5 min. This short drug±light interval was chosen
based on animal studies showing the great speci®city of BPD-
MA in targeting the neovasculature when used at a short drug±
light interval (Fingar et al., 1999; Major et al., 1999b). In
addition, we also planned to determine the optimal concentra-
tion of this drug required for selective endometrial tissue
destruction.
Figure 1. (A) Cross-section of a rat uterus after i.v. injection of veterpor®n at 2 mg/kg. There are acute in¯ammatory in®ltrates in the stroma
and destruction of the myometrium. The box indicates the acute in¯ammatory reaction involving polynuclear neutrophils. (B) An example of
a rat injected with veterpor®n at 1 mg/kg. Note the complete absence of the endometrial glands (arrow) with complete loss of the myometrial
thickness (arrow head). (C) At 0.25 mg/kg there is complete absence of the endometrial glands with no in¯ammation or necrosis (arrow).
Half of the myometrium thickness is still conserved (bar). (D) At 0.0625 mg/kg there is incomplete destruction of the endometrial glands
(arrow) despite the complete presence of the myometrium (bar). (E) In the normal control as well as in the right horn (internal control) there





Thirty-two female Sprague±Dawley rats weighing 250±350 g were
placed in a controlled environment with free access to food and water.
The guidelines for animal care and use were approved by the ethics
committee of the University Hospital of Geneva and the veterinarian's
of®ce of the Canton of Geneva (no. 31.1.1041/2035/l). Vertepor®n
(VisudyneÔ; Novartis Pharmaceuticals, Inc., Basel, Switzerland) was
used for this study. Rats were anaesthetized by i.m. injection of
ketamine (80 mg/kg) and xylazine (10 mg/kg). A catheter through the
jugular vein was used to administer the drug, which was diluted in 5%
dextrose. We divided our rats into six groups, four in each group,
depending on the dose of vertepor®n: group I (2 mg/kg), group II
(1 mg/kg), group III (0.5 mg/kg), group IV (0.25 mg/kg), group V
(0.125 mg/kg) and group VI (0.0625 mg/kg). In addition, eight rats
that received NaCl (0.9%) were used as negative controls. Five
minutes after drug injection, PDT was carried out. A 3 cm midline
incision through the lower abdomen was used to introduce an optical
®bre connected to a diode laser operating at 630 nm (Diomed,
Cambridge, UK). The light applicator was ®tted snugly into the left
uterine horn superior to the bifurcation of the uterus. The right horn
(control) was shielded from light with gauze soaked with physio-
logical saline kept at body temperature. The light was delivered to the
uterine cavity via a 3 cm long, 1.2 mm diameter FLEX DIFFUSER
(model FX1; Miravant, Santa Barbara, CA, USA) at a rate of 100 mW/
cm of ®bre, and the time of exposure was 500 s, resulting in a rate of
120 J/cm2; this was the same for all rats. The abdomens were sutured
and the animals returned to their cages. Based on numerous studies
showing that major histological changes of the rat endometrium after
PDT can be seen as early as 1 day after and remain unchanged 4 days
later (Major et al., 1999a; 2002), a 4-day interval between laser
exposure and histological examination was chosen. Rats were ®rst
anaesthetized with iso¯urane (3%) and then euthanized by
intracardiac injection of KCl solution (15%). The rat uteri were
placed in 4% formaldehyde for ®xation and then cut for processing.
The specimens were embedded in paraf®n and stained with
haematoxylin and eosin (HE). The sections were examined by light
microscopy. In each rat, HE sections of the left horn were compared
with the right horn (internal control). The endometrial glands were
counted on a complete cross section at three different levels from the
untreated horn and treated uterine horns. The myometrium thickness
was measured with a light microscope with a calibrated ocular scale.
Measurements of the myometrium from the three ideal cross-sections
were registered from the treated and untreated uterine horns. The
presence or absence of acute in¯ammation, as de®ned by the presence
of polynuclear segmented neutrophils seen in the endometrial stroma,
was also recorded.
Statistical analysis
Comparisons between the treated and the untreated sides were
performed using Student's paired t-test for continuous variables
(number of glands and myometrium thickness, averaged over three
measures for each data point) and Wilcoxon signed-rank test for the
binary variable (in¯ammation status). When the overall differences of
continuous response variables were statistically signi®cant, we
performed multiple comparisons for each vertepor®n concentration
while adjusting the appropriate signi®cance levels according to
Bonferroni's correction (P threshold becomes 0.05/6 = 0.0083). As
there were not enough observations to ful®l ANOVA assumptions, we
checked for the equality of distribution of the response variables
among the different levels of vertepor®n concentrations using the
Kruskal±Wallis test. Possible trends in dose-effects were evaluated
using linear regression with the continuous response measures as the
dependent variables and the vertepor®n concentration as the predictor.
A non-parametric test for trend across ordered group was applied to
evaluate the effect of vertepor®n concentration on the in¯ammation
status.
Results
On histological examination, there was glandular destruction
and myometrial loss in the uterine horns of all rats. We also
noticed changes in the wall of the blood vessels with ®brinoid
necrosis of the intima and thrombotic occlusions in some of the
lumens. In addition, we noted the presence of acute in¯am-
matory cell in®ltrates in the endometrial stroma. However,
these histological ®ndings differed in the degree of severity
depending on the vertepor®n dosage (Figure 1A±D). We found
a statistically signi®cant difference in the number of endo-
metrial glands between the treated and the untreated horns in
all six groups (P < 0.0001; Figure 2). When we compared the
number of glands between the untreated and treated uterine
horns of each rat in all of the six groups, there were signi®cant
differences between each of the six groups. However, when
taking into consideration all the multiple comparisons, by
applying Bonferroni's correction to the P values (meaning
signi®cance was now accepted when P < 0.0083), the group of
rats that maintained a signi®cant P value were groups I (P <
0.0079), II (P = 0.0045), III (P = 0.0028), IV (P = 0.0009) and
V (P = 0.0050), but not group VI (P = 0.0190). In addition, the
most evident difference in the number of glands was observed
in group IV, as seen in Figure 2. Figure 3 shows the difference
in myometrium thickness measured in the untreated and the
treated horn of each rat of the six groups. After Bonferroni's
correction, a signi®cant difference was seen in groups I (P =
0.0070) and II (P = 0.0086), but not in groups III (P = 0.0100),
IV (P = 0.0449), V (P = 0.0142) and VI (P = 0.1849). As for
acute in¯ammatory cells (AIC), they were present in all three
measurements (cross section) in groups I and II. In group III,
one rat had AIC in one measurement, one rat had AIC in two
Figure 2. Median and interquartile range for the number of glands
between the untreated uterine horn and treated horn in each of the
six treatment groups. P values after Bonferroni's correction: *P <
0.008; **P < 0.001. Circles represents the untreated horn and
triangles the treated horn.
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measurements and two rats had AIC in three measurements. No
AIC were registered in any of groups IV, V or VI. In addition,
during macroscopic organ dissection we noted adherence of the
colon to rat uteri in groups I and II, without organ perforation.
In contrast, the uteri in the control rats and the right untreated
horn of each of the 24 rats conserved a normal histology with
neither endometrial destruction nor myometrial loss
(Figure 1E).
Discussion
Hysterectomy has been considered the treatment of choice for
women suffering from dysfunctional uterine bleeding.
However, in a substantial percentage of patients, hysterectomy
results in morbidity and mortality, leading to a total health cost
exceeding US$5 billion in the USA (Lee et al., 1984; Carlson
et al., 1993). Thus, an alternative treatment with fewer side
effects and lower cost is needed, and PDT may well ®t this
pro®le. PDT has shown promising results in animal models
using different photosensitizers, such as BPD-MA or ALA,
with topical or systemic administration (Wyss et al., 1994a;b;
Gannon et al., 1995; Fehr et al., 1996a;b; Steiner et al., 1996).
Angiogenesis is observed not only in malignant tumours, but
also occurs in organs such as the ovary and endometrium
(Gargett and Rogers, 2001; Kurohane et al., 2001). By binding
to the low-density lipoprotein (LDL) receptors and internaliza-
tion into the cells via the endocytotic pathway, vertepor®n can
act with a degree of selectively on tissues expressing a high
density of LDL receptors. These tissues include those with
rapidly proliferating cells such as tumours, proliferating
endothelial cells and normal endometrial glands (Sayegh
et al., 1995; Renno and Miller, 2001). In addition, PDT can
easily be accomplished with a device of very small diameter
(<2 mm), thus avoiding the necessity for anaesthesia (such a
device was developed in collaboration with the Swiss Federal
Institute of Technology). For these reasons, veterpor®n-medi-
ated PDT appears to be the ideal means of endometrial ablation
in the clinical settings.
Studies evaluating PDT in endometrial ablation have
primarily used ALA as the photosensitizer, due to its rapid
elimination from the tissue. These studies targeted mainly the
cellular compartment (Wyss et al., 1994b; Gannon et al., 1995;
Fehr et al., 1996b; Steiner et al., 1996). A few studies have
evaluated the effect of BPD-MA-mediated PDT on endome-
trial tissue using topical application (Wyss et al., 1994a;
Hornung et al., 1998). To the best of our knowledge, the
present study is the ®rst in which a second-generation
photosensitizer, BPD-MA, was administrated by i.v. injection
followed by PDT only a few minutes after drug administration.
We decided to give vertepor®n by i.v. injection for two reasons,
®rst to test its use and ef®cacy in this mode of administration
and secondly to determine whether we can avoid intrauterine
application, thus making it more practical in the clinical setting
in future human application.
Vertepor®n used by systemic injection proved to be very
effective in endometrial glandular ablation at all concentra-
tions. The optimal drug concentration, de®ned as that which
causes total glandular destruction with minimal loss of the
myometrial thickness and minimal in¯ammatory reaction,
seemed to range from 0.25 to 0.125 mg/kg. The lowest dose
(0.0625 mg/kg) used, despite the good conservation of the
myometrial thickness, was not ef®cient for total glandular
ablation. With the highest concentration (2 and 1 mg/kg),
despite their ef®cacy on glandular destruction, a signi®cant loss
of myometrial thickness, severe in¯ammatory reaction and
adherence of the adjacent organ to the uterus was recorded.
Nevertheless, a total selectivity in terms of complete destruc-
tion of the endometrium without harm to the myometrium has
not been observed in the rat model. However, this could have
some advantage, as the destruction of a small proportion of the
inner myometrium might avoid the possibility of endometrial
regeneration. The long-term effect of vertepor®n on endome-
trial ablation needs to be evaluated in further studies. In the
human uterus, PDT provides a better chance of selective
destruction of the endometrium while conserving the myome-
trium, due to its thickness. The rather thick myometrium will
be protected from complete destruction, even in the absence of
complete tissue PDT selectivity, by the penetration depth of the
light being set at 630 or even at 690 nm.
In summary, using PDT shortly after vertepor®n adminis-
tration, thereby targeting the endometrial vasculature, results in
endometrial ablation with high ef®cacy. Thus, this therapy may
contribute to a new treatment modality for endometrial
ablation. Further studies using different drug/light doses and
intervals to increase the endometrial tissue selectivity are
underway.
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